tiprankstipranks
AEON Biopharma Halts Migraine Study and Evaluates Strategy
Company Announcements

AEON Biopharma Halts Migraine Study and Evaluates Strategy

Don't Miss our Black Friday Offers:

AEON Biopharma (AEON) has shared an update.

AEON has halted its Phase 2 study and related open label extension study on ABP-450 for migraine treatment after the trials failed to meet primary endpoints, though some secondary goals were achieved. Patients will continue to be monitored for safety. This decision will help AEON save cash as it considers future strategic directions.

Find detailed analytics on AEON stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAEON Biopharma Releases New Investor Presentation
TheFlyAeon Biopharma announces outcome from FDA biosimilar advisory meeting
TheFlyAeon Biopharma files $200M mixed securities shelf
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App